Mass screening for prostate cancer in Europe still not recommended

Apr 19, 2010

The European Association of Urology reiterated that it does not recommend a mass screening policy in Europe for men who are concerned over prostate cancer, a stance which reflects the position it issued last year regarding prostate cancer screening.

"We don't believe that the time has come for ," said EAU Secretary General. Per-Anders Abrahamsson in reply to a query on whether a mass screening policy in Europe would be eventually recommended.

At the media forum held this afternoon which focused on " in Europe- the debate continues" patient organizations, urological professionals and the European Union were represented. Abrahamsson said the EAU reiterates its official position which says that men should be properly informed first by their physician about the pros and cons of screening, such as a PSA test.

Also presenting their views were Prof. Louis Denis, chairperson of patient advocate group Europa Uomo and Alojz Peterle, member of the European Parliament.

" is one of the key concerns and goals that the European Parliament are working on and we believed that knowledge shared between the medical community, patients and governments is of crucial importance. We need to take action to now," said Peterle.

Denis, on the other hand, focused on strengthening the communication links between patients groups and the medical community as he pointed out that "…education of and proper awareness amongst patients lead to optimum treatment."

The debate on the need for prostate cancer screening came about following the release last year of two major trials, the European Randomised study of Screening for Prostate Cancer (ERSPC) in Europe and the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial in the US.

The ERSPC investigates the value of PSA driven screening in 162,387 men (age 55-70) from eight European countries. Amongst its preliminary conclusions are: men who decide to be PSA-tested have a 31% smaller chance of dying of prostate cancer within nine years and that a larger improvement is expected with longer follow-up.

The ERSPC added that the "possibility of overdiagnosis and overtreatment must be considered" by both the patient and his doctor.

Prof. Freddie Hamdy, moderator of the press forum, underscored that it is important that the media presents an accurate and balanced view to avoid overtreatment in patients whose risks for developing are low.

Explore further: Survival hope for melanoma patients thanks to new vaccine

Provided by European Association of Urology

not rated yet
add to favorites email to friend print save as pdf

Related Stories

PSA screening cuts deaths by 20 percent

Mar 18, 2009

Screening for prostate cancer can reduce deaths by 20%, according to the results of the European Randomized Study of Screening for Prostate Cancer (ERSPC) published online 1700 hours CET, today 18 March (NEJM, Online First*). ...

Recommended for you

Survival hope for melanoma patients thanks to new vaccine

14 minutes ago

(Medical Xpress)—University of Adelaide researchers have discovered that a new trial vaccine offers the most promising treatment to date for melanoma that has spread, with increased patient survival rates and improved ability ...

New clinical trial launched for advance lung cancer

3 hours ago

Cancer Research UK is partnering with pharmaceutical companies AstraZeneca and Pfizer to create a pioneering clinical trial for patients with advanced lung cancer – marking a new era of research into personalised medicines ...

User comments : 0

More news stories

Down's chromosome cause genome-wide disruption

The extra copy of Chromosome 21 that causes Down's syndrome throws a spanner into the workings of all the other chromosomes as well, said a study published Wednesday that surprised its authors.

New clinical trial launched for advance lung cancer

Cancer Research UK is partnering with pharmaceutical companies AstraZeneca and Pfizer to create a pioneering clinical trial for patients with advanced lung cancer – marking a new era of research into personalised medicines ...

Sony's PlayStation 4 sales top seven million

Sony says it has sold seven million PlayStation 4 worldwide since its launch last year and admitted it can't make them fast enough, in a welcome change of fortune for the Japanese consumer electronics giant.